Pharmacoeconomic evaluation of warfarin pharmacogenomics

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 3, 2011, Pages 435-441

  You, Joyce Hs ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

cost; cost effectiveness; pharmacoeconomics; pharmacogenomics; warfarin

Indexed keywords

ACENOCOUMAROL; CYTOCHROME P450 2C9; MENADIONE EPOXIDE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DNA POLYMORPHISM; DRUG DOSE REGIMEN; DRUG EFFICACY; ECONOMIC EVALUATION; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; NONHUMAN; PHARMACOGENOMICS; QUALITY ADJUSTED LIFE YEAR; STROKE; THROMBOEMBOLISM;

ALGORITHMS; ANTICOAGULANTS; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PHARMACOGENETICS; QUALITY-ADJUSTED LIFE YEARS; WARFARIN;

EID: 79251491073     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.521153     Document Type: Article

References (42)

1. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin-nature or nuture? Clin Pharmacol Ther 2001;70:159-64
2. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-19
3. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002;287:1690-8
4. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000;96:1816-19
5. D'Andrea G, D'Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9
6. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-70
7. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93
8. Borgiani P, Ciccacci C, Forte V, et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009;10:261-6
9. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirement in African Americans. Clin Pharmacol Ther 2010;87:445-51
10. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33
11. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G > A) and CYP 2C9 genotypes. Clin Chem 2007;53:1199-205
12. Li C, Schwarz UI, Ritchie MD, et al. Relative contribution of CYP 2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 2009;113:3925-30
13. Carlquist JF, Horne BD, Muhlestein JB, et al. Genotypes of the cytochrome p450 isoform, CYP2C9 and the vitamine K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006;22:191-7
14. Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92
15. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-64
16. Wu AHB, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 2008;9:169-78
17. Miao L, Yang J. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007;63:1135-41
18. Huang SW, Chen HS, Wang XQ, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics 2009;19:226-34
19. Wen SM, Lee MTM, Chen JJ, et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin Pharmacol Ther 2008;84:83-9
20. You JHS, Wong RSM, Waye MMY, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis 2010: published online 29 June 2010, doi:10.1007/s11239-010-0497-x
21. Lenzini PA, Grice CG, Milligan PE, et al. Laboratory and clinical outcomes of pharmacogenetics vs. clinical protocols for warfarin initiation in orthopedic patients. J Thromb Haemost 2008;6:1655-62
22. Ross KA, Bigham AW, Edwards M, et al. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010: published online 17 June 2010, doi:10.1038/jhg.2010.73
23. Veenstra DL, You JHS, Rieder MJ, et al. Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005;15:687-91
24. Scott SA, Khasawneh R, Peter I, et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010;11:781-91
25. Hillman MA, Wilke RA, Yale SH, et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005;3:137-45
26. Anderson JL, Horne BD, Stevens SM, et al. Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007;116:2563-70
27. Caraco Y, Blotnick S, Muzkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective, randomized, controlled study. Clin Pharmacol Ther 2008;83:460-70
28. Kangelaris KN, Bent S, Nussbaum RL, et al. Genetic testing before anticoagulation? A systematic review of harmacogenetics dosing of warfarin. J Gen Intern Med 2009;24:656-64
29. Kim MJ, Huang SM, Meyer UA, et al. A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J Clin Pharmacol 2009;49:138-46
30. Wadelius M. Use of pharmacogenetics in guiding treatment with warfarin. Clin Chem 2009;55:709-11
31. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 2009;151:270-3
32. Eby CS. Pharmacogenetics-based initial dosing of warfarin: not ready for prime time. Clin Chem 2009;55:712-14
33. Clarification ofoptimal anticoagulation through genetics (COAG). Available from: http://clinicaltrials.gov/ct2/show/NCT00839657 [Last accessed 5 July 2010]
34. van Schie RMF, Wadelius M, Kamali F, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009;10:1687-95
35. You JHS, Chan FWH, Wong RSM, Cheng G. The potential clinical and economic outcomes of pharmacogenetics-oriented management of warfarin therapy-a decision analysis. Thromb Haemost 2004;92:590-7
36. Schalekamp T, Boink GJ, Visser LE, et al. CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clin Pharmacol Ther 2006;79:511-20
37. McWilliam A, Lutter R, Nardinelli C. Healthcare impact of personalized medicine using genetic testing: an exploratory analysis for warfarin. Pers Med 2008;5:279-84
38. Eckman MH, Rosand R, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with non-valvular atrial fibrillation. Ann Intern Med 2009;150:73-83
39. You JHS, Tsui KKN, Wong RSM, Cheng G. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients initiating warfarin therapy. Clin Pharmacol Ther 2009;86:540-7
40. Patrick AR, Avorn J, Choudhry NK. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2009: published online 21 July 2009, doi:10.1161/circoutcomes.108. 808592
41. Meckley LM, Gudgeon JM, Anderson JL, et al. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics 2010;28:61-74
42. Maurice CB, Barua PK, Simses D, et al. Comparison of assay systems for warfarin-related CYP2C9 and VKORC1 genotyping. Clin Chim Acta 2010;411:947-54